Trials in Virginia.

This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…

This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…

This study looked at whether sticking with CPAP, the mask-and-airflow machine for sleep apnea, is linked to memory, thinking, and daily function after one year…

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…

This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…

This trial is testing whether memantine, an existing drug already used for moderate-to-severe Alzheimer's symptoms, can be given years before symptoms to help…

This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…

This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…

Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…

This is an observational study, so nothing is being tested as a treatment. Researchers are looking at how the genes and symptoms of ALS and related conditions,…

This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…

This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild…

This trial is testing a community health worker program called PLAN, designed to help Korean American elders who may have undiagnosed dementia get connected to…

This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…

This trial tests AMT-130, a gene therapy delivered by brain surgery into a deep brain region called the striatum, in adults with early Huntington's disease. It…

PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…

This trial tests whether CBD oil with no THC (the compound that causes a high) can ease agitation in people who already have Alzheimer's dementia. It also…

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…

This study is not a clinical drug or device trial. Researchers are interviewing extended family caregivers of people living with dementia to learn how they…

The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…

This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…

This is not a treatment trial. APHELEIA is a prescreening registry designed to find and evaluate people who might qualify for future Alzheimer's therapeutic…

This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…

This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…

This trial tests whether IGC-AD1, a twice-daily oral THC-based medication, can ease agitation in people with mild to severe Alzheimer's dementia. Agitation…

This trial tests whether an internet-delivered program of cognitive behavioral therapy for insomnia (called SHUTi) improves sleep and thinking skills in adults…

This trial is studying a small brain region called the locus coeruleus and how its connections to attention networks may explain why older adults get more…

This study is not a treatment trial. Researchers are comparing gut bacteria and blood markers in three groups: people with Alzheimer's dementia, their spouses,…

This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…

This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…

This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…

This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…

This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…

This trial tests whether a daily pill called acoramidis can delay or prevent heart or nerve damage in people who carry an inherited TTR gene variant but have…

This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…

This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker…

This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…

This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…

This trial is testing a new low-dose formulation of rifaximin, an antibiotic that stays in the gut rather than entering the bloodstream, to see whether it can…

This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…

This trial tests ONO-2020, an experimental pill that works on gene regulation, in people already diagnosed with mild to moderate Alzheimer's. Researchers want…

This trial is testing whether a drug called ACP-204 reduces hallucinations and delusions in people with Lewy body dementia or Parkinson's disease dementia,…

This trial follows people with Lewy body dementia who experience psychosis, such as hallucinations or delusions. It tests an experimental drug, ACP-204, taken…

This is an open-label extension study, meaning all participants receive the drug GSK4527226 — no placebo. It is only open to people who already completed the…

This trial is testing trontinemab, an anti-amyloid antibody drug, against a placebo in people with early Alzheimer's disease — specifically those at the MCI or…

This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive…